144 related articles for article (PubMed ID: 11936837)
1. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo.
Mohammad A; Wang J; McNeill JH
Mol Cell Biochem; 2002 Jan; 229(1-2):125-8. PubMed ID: 11936837
[TBL] [Abstract][Full Text] [Related]
2. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
[TBL] [Abstract][Full Text] [Related]
3. In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats.
Marzban L; Bhanot S; McNeill JH
Mol Cell Biochem; 2001 Jul; 223(1-2):147-57. PubMed ID: 11681716
[TBL] [Abstract][Full Text] [Related]
4. In vivo effects of vanadium in diabetic rats are independent of changes in PI-3 kinase activity in skeletal muscle.
Mohammad A; Bhanot S; McNeill JH
Mol Cell Biochem; 2001 Jul; 223(1-2):103-8. PubMed ID: 11681710
[TBL] [Abstract][Full Text] [Related]
5. Effect of vanadium on insulin sensitivity and appetite.
Wang J; Yuen VG; McNeill JH
Metabolism; 2001 Jun; 50(6):667-73. PubMed ID: 11398143
[TBL] [Abstract][Full Text] [Related]
6. Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats.
Yuen VG; Vera E; Battell ML; Li WM; McNeill JH
Diabetes Res Clin Pract; 1999 Jan; 43(1):9-19. PubMed ID: 10199584
[TBL] [Abstract][Full Text] [Related]
7. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM; Risovic V; Yuen VG; McNeill JH
J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV).
Li M; Ding W; Baruah B; Crans DC; Wang R
J Inorg Biochem; 2008 Oct; 102(10):1846-53. PubMed ID: 18728000
[TBL] [Abstract][Full Text] [Related]
9. Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats.
Yuen VG; Pederson RA; Dai S; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1996 Sep; 74(9):1001-9. PubMed ID: 8960391
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component.
Peters KG; Davis MG; Howard BW; Pokross M; Rastogi V; Diven C; Greis KD; Eby-Wilkens E; Maier M; Evdokimov A; Soper S; Genbauffe F
J Inorg Biochem; 2003 Aug; 96(2-3):321-30. PubMed ID: 12888267
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
12. Effects of bis(maltolato) oxovanadium (IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats.
Bhanot S; Girn J; Poucheret P; McNeill JH
Mol Cell Biochem; 1999 Dec; 202(1-2):131-40. PubMed ID: 10706003
[TBL] [Abstract][Full Text] [Related]
13. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
Marzban L; Rahimian R; Brownsey RW; McNeill JH
Endocrinology; 2002 Dec; 143(12):4636-45. PubMed ID: 12446591
[TBL] [Abstract][Full Text] [Related]
15. Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats.
Bhanot S; Bryer-Ash M; Cheung A; McNeill JH
Diabetes; 1994 Jul; 43(7):857-61. PubMed ID: 8013747
[TBL] [Abstract][Full Text] [Related]
16. Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatase-1 activity.
Semiz S; McNeill JH
Mol Cell Biochem; 2002 Jul; 236(1-2):123-31. PubMed ID: 12190110
[TBL] [Abstract][Full Text] [Related]
17. The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.
Winter PW; Al-Qatati A; Wolf-Ringwall AL; Schoeberl S; Chatterjee PB; Barisas BG; Roess DA; Crans DC
Dalton Trans; 2012 Jun; 41(21):6419-30. PubMed ID: 22569684
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B.
Wu Y; Ou-Yang JP; Wu K; Wang Y; Zhou YF; Wen CY
Acta Pharmacol Sin; 2005 Mar; 26(3):345-52. PubMed ID: 15715932
[TBL] [Abstract][Full Text] [Related]
19. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; Thompson KH; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):270-6. PubMed ID: 8402391
[TBL] [Abstract][Full Text] [Related]
20. The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
DabroĊ W; Dziga D; Kordowiak AM
Pol J Pathol; 2002; 53(4):205-13. PubMed ID: 12597338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
